# Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus Pembrolizumab

> **NCT06648057** · — · RECRUITING · sponsor: **CHA University** · enrollment: 100 (estimated)

## Conditions studied

- Biliary Tract Cancer
- Cholangiocarcinoma

## Interventions

- **DRUG:** lenvatinib plus pembrolizumab

## Key facts

- **NCT ID:** NCT06648057
- **Lead sponsor:** CHA University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-23
- **Primary completion:** 2026-09-23
- **Final completion:** 2026-12-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06648057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06648057, "Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus Pembrolizumab". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06648057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*